Enterprise Value

509.6M

Cash

140.8M

Avg Qtr Burn

-19.15M

Short % of Float

22.92%

Insider Ownership

0.88%

Institutional Own.

62.56%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease

Big Mover™

Susp. Mover™

Phase 2b

Data readout

HepTCell Details
Chronic hepatitis B

Big Mover™

Susp. Mover™

Phase 2

Data readout

Phase 2

Update

Phase 1b

Update

NasoShield (Vaccine) Details
Anthrax, Bacterial infection

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued